To complement ongoing phase IV clinical studies to investigate the phenotype and ocular biomarkers of conjunctivitis in patients (40), we used what we believe to be a novel skin inflammation–evoked conjunctivitis model to further investigate potential effects of IL-4Rα inhibition in mice. This evidence concerns the gene IL4R and conjunctivitis.